Skip to main content

RADIOQUIMICA INNOVADORA CON 18F, 11C Y 13N: REACCIONES DE INTERCAMBIO ISOTOPICO INDUCIDAS POR IONES, TIPO NEGISHI Y ENZIMATICAS PARA EXPANDIR EL CATALOGO DE TRAZADORES PET.

CTQ2017-87637-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre ASOCIACIÓN CENTRO DE INVESTIGACION COOP. BIOMATERIALES

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Radiochemical examination of transthyretin (TTR) brain penetration assisted by iododiflunisal, a TTR tetramer stabilizer and a new candidate drug for AD

  • Ríos, Xabier
  • Gómez-Vallejo, Vanessa
  • Martín, Abraham
  • Cossío, Unai
  • Morcillo, Miguel Ángel
  • Alemi, Mobina
  • Cardoso, Isabel Santos
  • Quintana, Jordi
  • Jiménez-Bar̀bero, Jesús J.
  • Cotrina, Ellen Y.
  • Valencia Parera, Gregorio
  • Arsequell, Gemma
  • Llop Roig, Jordi
It is well settled that the amyloidogenic properties of the plasma protein transporter transthyretin (TTR) can be modulated by compounds that stabilize its native tetrameric conformation. TTR is also present in cerebrospinal fluid where it can bind to Aβ-peptides and prevent Aβ aggregation. We have previously shown that treatment of Alzheimer’s Disease (AD) model mice with iododiflunisal (IDIF), a TTR tetramer stabilizing compound, prevents AD pathologies. This evidence positioned IDIF as a new lead drug for AD. In dissecting the mechanism of action of IDIF, we disclose here different labeling strategies for the preparation of 131I-labeled IDIF and 131I- and 124I-labeled TTR, which have been further used for the preparation of IDIF-TTR complexes labeled either on the compound or the protein. The biodistribution of all labeled species after intravenous administration has been investigated in mice using ex vivo and in vivo techniques. Our results confirm the capacity of TTR to cross the blood brain barrier (BBB) and suggest that the formation of TTR-IDIF complexes enhances BBB permeability of both IDIF and TTR. The increased TTR and IDIF brain concentrations may result in higher Aβ-peptide sequestration capacity with the subsequent inhibition of AD symptoms as we have previously observed in mice. © 2019, The Author(s)., The work was supported by a grant from the Fundació Marató de TV3 (Neurodegenerative Diseases Call, Project Reference 20140330-31-32-33-34, http://www.ccma.cat/tv3/marato/en/ projectes-financats/2013/212/). The group at CIC biomaGUNE also acknowledges MINECO (Spain) for funding through Grant CTQ2017-87637-R. I. Cardoso worked under the Investigator FCT Program which is financed by national funds through the Foundation for Science and Technology (FCT, Portugal) and co-financed by the European Social Fund (ESF) through the Human Potential Operational Programme (HPOP), type 4.2 - Promotion of Scientific Employment., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Undiscovered Roles for Transthyretin: From a Transporter Protein to a New Therapeutic Target for Alzheimer’s Disease

  • Gião, Tiago
  • Saavedra, Joana
  • Cotrina, Ellen Y.
  • Quintana, Jordi
  • Llop Roig, Jordi
  • Arsequell, Gemma
  • Cardoso, Isabel
© 2020 by the authors., Transthyretin (TTR), an homotetrameric protein mainly synthesized by the liver and the choroid plexus, and secreted into the blood and the cerebrospinal fluid, respectively, has been specially acknowledged for its functions as a transporter protein of thyroxine and retinol (the latter through binding to the retinol-binding protein), in these fluids. Still, this protein has managed to stay in the spotlight as it has been assigned new and varied functions. In this review, we cover knowledge on novel TTR functions and the cellular pathways involved, spanning from neuroprotection to vascular events, while emphasizing its involvement in Alzheimer’s disease (AD). We describe details of TTR as an amyloid binding protein and discuss its interaction with the amyloid Aβ peptides, and the proposed mechanisms underlying TTR neuroprotection in AD. We also present the importance of translating advances in the knowledge of the TTR neuroprotective role into drug discovery strategies focused on TTR as a new target in AD therapeutics., The group from i3S acknowledges for funding through a grant from Norte2020, Portugal (Norte-01-0145FEDER-000008- Porto Neurosciences), and Fundação Millennium bcp. The group at CIC biomaGUNE acknowledges the Spanish Ministry of Economy and Competitiveness, grant number CTQ2017-87637-R., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

PLGA protein nanocarriers with tailor-made fluorescence/MRI/PET imaging modalities

  • Zhang, Yajie
  • García Gabilondo, Miguel
  • Grayston, Alba
  • Feiner, Irene V. J.
  • Anton Sales, Irene
  • Azevedo Loiola, Rodrigo
  • Llop, Jordi
  • Ramos Cabrer, Pedro
  • Barba, Ignasi
  • Garcia Dorado, David
  • Gosselet, Fabien
  • Rosell, Anna
  • Roig Serra, Anna
Designing theranostic nanocarriers with high protein payload and multimodality tracking without cross interferences between the different imaging probes and the delicate protein cargo is challenging. Here, chemical modifications of poly(lactic-co-glycolic acid) (PLGA) to produce nanocapsules (NCs) that incorporate several imaging moieties are reported. The biocompatible and biodegradable PLGA-NCs can be endowed with a magnetic resonance imaging (MRI) reporter, two fluorescence imaging probes (blue/NIR) and a positron emission tomography (PET) reporter. The modular integration of these imaging moieties into the shell of the NCs is successfully achieved without affecting the morphochemical properties of the nanocarrier or the protein loading capacity. In vivo biodistribution of the NCs is monitored by MRI, PET and NIRF and the results from different techniques are analyzed comparatively. The viabilities of two different human endothelial cells in vitro show no toxicity for NC concentration up to 100 μg mL−1 . The morbidity of mice for 2 weeks after systemic administration and the hepatic/pancreatic enzymes at the plasma level indicate their in vivo biosafety. In summary, the new theranostic PLGA nanoplatform presented here shows versatile in vitro/in vivo multimodal imaging capabilities, excellent biosafety and over 1 wt% protein loading., The Acciones Complementarias program from the Instituto de Salud Carlos III, Spain, co-financed by the European Regional Development Fund (AC17/00004 grant) as part of the MAGBBRIS project (Euronanomed III 8th joint call), and the RETICS INVICTUS RD16/0019/0021 are acknowledged. The Miguel Servet program (CPII15/00003) and PFIS program (FI17/00073) from Fondo de Investigaciones SanitariasInstituto de Salud Carlos III and ERDF supported A. Rosell and A. G. research contracts. This work was also partially supported by the Spanish Ministry of Science, Innovation and Universities through the grants PCIN-2017-090, RTI2018- 096273-B-I00, CTQ2017-87637-R, SAF2017-87670-R, SEV-2015- 0496 and MDM-2017-0720 and by the Generalitat de Catalunya grants (2017SGR765 & 2017SGR1427). Yajie Zhang is supported by the China Scholarship Council (CSC). FG and RAL are supported by the French national agency (ANR) through the grant ANR-17-ENM3-0005-01. The authors thank Dr Vanessa GómezVallejo, Dr Unai Cossío, Dr Xabier Rios and Zuriñe Baz for support in labelling and PET in vivo experimentation. We acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

MRI/Photoluminescence Dual-Modal Imaging Magnetic PLGA Nanocapsules for Theranostics

  • Zhang, Yajie
  • García Gabilondo, Miguel
  • Rosell, Anna
  • Roig Serra, Anna
Developing multifunctional and biocompatible drug delivery nanoplatforms that integrate high drug loads and multiple imaging modalities avoiding cross-interferences is extremely challenging. Here we report on the successful chemical reaction of the high quantum yield biodegradable and photoluminescent polyester (BPLP) with the poly(lactic-co-glycolic acid) (PLGA) polymer to fabricate biocompatible photoluminescent nanocapsules (NCs). Furthermore, we transform the PLGA-BPLP NCs into a magnetic resonance (MR)/photoluminescence dual-modal imaging theranostic platform by incorporating superparamagnetic iron oxide nanoparticles (SPIONs) into the polymeric shell. In vitro phantoms confirmed the excellent MRI-r2 relaxivity values of the NCs whilst the cellular uptake of these NCs was clearly observed by fluorescence optical imaging. Besides, the NCs (mean size ~270 nm) were loaded with ~1 wt% of a model protein (BSA) and their PEGylation provided a more hydrophilic surface. The NCs show biocompatibility in vitro, as hCMEC/D3 endothelial cells viability was not affected for particle concentration up to 500 μg/mL. Interestingly, NCs decorated with SPIONs can be exploited for magnetic guiding and retention., This work was partially supported by the Spanish Ministry of Science, Innovation and Universities through the grants PCIN-2017-090, RTI2018-096273-B-I00, CTQ2017-87637-R, SAF2017-87670-R, SEV-2015-0496 and MDM-2017-0720 and by the Generalitat de Catalunya grants (2017SGR765 & 2017SGR1427). Yajie Zhang was supported by the China Scholarship Council (CSC). The Acciones Complementarias program from the Instituto de Salud Carlos III, Spain, co-financed by the European Regional Development Fund (AC17/00004 grant) as part of the MAGBBRIS project (Euronanomed III 8th joint call), and the RETICS INVICTUS RD16/0019/0021 were acknowledged. Miguel Servet program (CPII15/00003) from Fondo de Investigaciones Sanitarias-Instituto de Salud Carlos III and ERDF, supported A. Roig research contract., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Radiolabeled Cobaltabis(dicarbollide) Anion–Graphene Oxide Nanocomposites for In Vivo Bioimaging and Boron Delivery

  • Ferrer Ugalde, Albert
  • Sandoval, Stefania
  • Pulagam, Krishna Reddy
  • Muñoz Juan, Amanda
  • Laromaine, Anna
  • Llop, Jordi
  • Tobias, Gerard
  • Núñez Aguilera, Rosario
A carbon-based hybrid nanocomposite, which consists of monoiodinated boron-cluster derivatives covalently attached to graphene oxide, is hereby introduced. This GO-I-COSAN has been synthesized using a novel boron-rich cobaltabis(dicarbollide) precursor with one iodide group attached to one of the boron atoms of the cluster (I-COSAN) and designed to be subsequently labeled with radioactive 124I for its use in positron emission tomography (PET). In vitro cytotoxicity studies of GO-I-COSAN with HeLa cells at different concentrations up to 48 h proved that the cell mortality was lower than 10%, indicating minimal cytotoxicity of the nanomaterial. Remarkably, internalization of the nanomaterial by cells was confirmed by transmission electron microscopy, which indicated its accumulation in the cytoplasm, without causing changes in either the size or morphology of the cells. Additionally, in vivo tests using Caenorhabditis elegans confirmed that GO-I-COSAN could be ingested by the worms, showing no significant damage and very low toxicity, which supports the results observed in the in vitro studies. Radioisotopic labeling of I-COSAN using a palladium-catalyzed isotopic exchange reaction with Na[124I]I and its subsequent functionalization onto GO was performed successfully, leading to formation of the radioactive nanocomposite GO-[124I]I-COSAN, which was quickly injected in mice. PET images at different times revealed excellent in vivo stability of the developed nanomaterial. No activity in thyroid and stomach was observed even at long times, proving that iodide did not detach from the material. GO-[124I]I-COSAN presented a favorable biodistribution profile, being mainly accumulated in the liver and slightly in the lung, with a long residence time on blood and progressive elimination via the gastrointestinal tract. It is noteworthy that the high boron content of this material paves the way toward theranostics because it benefits of a traceable boron delivery for boron neutron capture therapy., This work was supported by the Spanish Ministry of Science and Innovation MICINN, through the Severo Ochoa Program for Centers of Excellence FUNFUTURE (CEX2019-000917- S), for funding with an internal Severo Ochoa FIP project. J.L. thanks the Spanish Ministry of Economy and Competitiveness for funding through Grant CTQ2017-87637-R. Part of the work was conducted under the Maria de Maeztu Units of Excellence Programme (Grant MDM-2017-0720). A.M.-J. and A.L. are thankful for financial support from the Spanish Ministry of Science and Innovation through Project RTI2018- 096273-B-I00 and a Ph.D. scholarship for A.M.J. (FPU18/ 05190) and the Generalitat de Catalunya with Projects 2017SGR765 and 2017SGR581. A.M.-J. and A.L. participated in the MICINN, “Research Networks” nanoCARE (RED2018- 102469-T). This work has been conducted within the Biotechnology Doctoral Program of the Autonomous University of Barcelona (A.M.J). The authors thank the staff from the Servei de Cultius Cel·lulars and Servei de Microscopia, ̀ both at the UAB, for performing the cytotoxicity studies, cellular uptake analysis, and HRTEM., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Therapeutic Pretargeting with Gold Nanoparticles as Drug Candidates for Boron Neutron Capture Therapy

  • Feiner, Irene V. J.
  • Pulagam, Krishna R.
  • Gómez-Vallejo, Vanessa
  • Zamacola, Kepa
  • Baz, Zuriñe
  • Caffarel, María M.
  • Lawrie, Charles H.
  • Ruiz-de-Angulo, Ane
  • Carril, Mónica
  • Llop, Jordi
Boron neutron capture therapy (BNCT) is a binary approach for cancer treatment in which boron-10 atoms and thermal neutrons need to colocalize to become effective. Recent research in the development of BNCT drug candidates focuses increasingly on nanomaterials, with the advantages of high boron loadings and passive targeting due to the enhanced permeability and retention (EPR) effect. The use of small boron-rich gold nanoparticles (AuNPs) in combination with a pretargeting approach is proposed. Small sized polyethylene glycol–stabilized AuNPs (core size 4.1 ± 1.5 nm), are synthesized and functionalized with thiolated cobalt bis(dicarbollide) and tetrazine. To enable in vivo tracking of the AuNPs by positron emission tomography (PET), the core is doped with [64Cu]CuCl2. For the pretargeting approach, the monoclonal antibody Trastuzumab is functionalized with trans-cyclooctene-N-hydroxysuccinimide ester. After proving in vitro occurrence of the antibody conjugation onto the AuNPs by click reaction and the low toxicity of the AuNPs, the boron delivery system is evaluated in vivo using breast cancer xenograft bearing mice and PET imaging. Tumor uptake due to the EPR effect can be witnessed with ≈5% injected dose (ID) cm−3 at 24 h postinjection, but with slower clearance than expected. Therefore, no increased retention can be observed using the pretargeting strategy., The project was carried out under the H2020—MSCA-ITN-2015 program, Grant Agreement No. 675417. J.L. thanks the Spanish Ministry of Economy and Competitiveness (Project No. CTQ2017-87637-R) for financial support. Part of the work has been performed under the Maria de Maeztu Units of Excellence Program from the Spanish State Research Agency (Grant No. MDM-2017-0720)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MRI/Photoluminescence Dual-Modal Imaging Magnetic PLGA Nanocapsules for Theranostics

  • Zhang, Yajie|||0000-0003-1566-1007
  • García-Gabilondo, Miguel|||0000-0002-2015-2621
  • Rosell Novel, Anna|||0000-0003-1082-3599
  • Roig i Serra, Anna|||0000-0001-6464-7573
Developing multifunctional and biocompatible drug delivery nanoplatforms that integrate high drug loads and multiple imaging modalities avoiding cross-interferences is extremely challenging. Here we report on the successful chemical reaction of the high quantum yield biodegradable and photoluminescent polyester (BPLP) with the poly(lactic-co-glycolic acid) (PLGA) polymer to fabricate biocompatible photoluminescent nanocapsules (NCs). Furthermore, we transform the PLGA-BPLP NCs into a magnetic resonance (MR)/photoluminescence dual-modal imaging theranostic platform by incorporating superparamagnetic iron oxide nanoparticles (SPIONs) into the polymeric shell. In vitro phantoms confirmed the excellent MRI-r relaxivity values of the NCs whilst the cellular uptake of these NCs was clearly observed by fluorescence optical imaging. Besides, the NCs (mean size ~270 nm) were loaded with ~1 wt% of a model protein (BSA) and their PEGylation provided a more hydrophilic surface. The NCs show biocompatibility in vitro, as hCMEC/D3 endothelial cells viability was not affected for particle concentration up to 500 μg/mL. Interestingly, NCs decorated with SPIONs can be exploited for magnetic guiding and retention.